Search

Biohaven has [ABSTRACT FROM AUTHOR]

AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate Dato-DXd has again failed to improve overall survival in a phase 3 trial. [ABSTRACT FROM AUTHOR]

Sanofi linked the BTK inhibitor to a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive MS. [ABSTRACT FROM AUTHOR]

Slow enrollment in a key clinical trial has driven Genfit to rework the protocol to try to keep the study on track. [ABSTRACT FROM AUTHOR]

The biotech came out swinging after the blow, accusing the FDA of sending a complete response letter that generally disregarded the evidence. [ABSTRACT FROM AUTHOR]

Achilles is stopping work on its clinical-phase cell therapy, looking into deals linked to other modalities and preparing to lay off staff. [ABSTRACT FROM AUTHOR]

Novo Nordisk agreed to pay NanoVation up to $600 million to collaborate on programs built on technology for targeting cells outside the liver. [ABSTRACT FROM AUTHOR]

A phase 1 that combined the candidate with bevacizumab reported a 21.9% response rate, including efficacy in patients with prior immunotherapy use. [ABSTRACT FROM AUTHOR]

The trial hit its primary endpoint, boosting plans to take a second shot at FDA approval, but two more people died and the OS data are immature. [ABSTRACT FROM AUTHOR]

Immatics is the latest partner to get a termination notice, leaving it in full control of a bispecific that BMS picked up for $150 million in 2021. [ABSTRACT FROM AUTHOR]

Boehringer has ended a decade of industrywide failures in idiopathic pulmonary fibrosis with a phase 3 win for a potentially first-in-class drug. [ABSTRACT FROM AUTHOR]

Cancer patients with wasting syndrome gained weight after taking a Pfizer antibody, leading the firm to target a 2025 start for its pivotal program. [ABSTRACT FROM AUTHOR]

AstraZeneca has shared an early look at its in-house ADCs, publishing phase 1 data on assets that could compete with molecules from AbbVie and Pfizer. [ABSTRACT FROM AUTHOR]

The biotech was unable to replicate the cognition signal it saw in an earlier midphase study, prompting it to stop development of luvadaxistat. [ABSTRACT FROM AUTHOR]

The National Academies is recommending the FDA and European Medicines Agency implement a "navigation service" to advise on regulatory pathways. [ABSTRACT FROM AUTHOR]

Sanofi has made a late entry to the radioligand party, paying 100 million euros for a neuroendocrine tumor drug that is nearing a filing for approval. [ABSTRACT FROM AUTHOR]

Moderna has vowed to cut R&D spendin [ABSTRACT FROM AUTHOR]

Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and highlighting the potenti [ABSTRACT FROM AUTHOR]

CEO Neil Kumar said the data "are not yet transformational," driving BridgeBio to shift its focus to other drug candidates and ways to treat disease. [ABSTRACT FROM AUTHOR]

With Tepezza on the market, the data leave scope to question whether the biotech has done enough to differentiate its asset and unseat the incumbent. [ABSTRACT FROM AUTHOR]

AstraZeneca and Daiichi have shared the OS data with regulators that are reviewing filings for approval of Dato-DXd. [ABSTRACT FROM AUTHOR]

Relay beat its survival goal in the study, positioning the biotech to start a pivotal trial that could establish it as a challenger to AstraZeneca. [ABSTRACT FROM AUTHOR]

Merck & Co.'s long-running effort to land a punch on small cell lung cancer (SCLC) has racked up a small victory. [ABSTRACT FROM AUTHOR]

Novartis is paying Voyager $15 million to take up its option on a novel capsid for use in a rare neurological disease gene therapy program. [ABSTRACT FROM AUTHOR]

Eli Lilly has vaulted into an AI-enabled drug discovery deal, partnering with RNA specialist Genetic Leap in a pact worth up to $409 million in upfront and milestone payments. [ABSTRACT FROM AUTHOR]

Fosgonimeton was no better than placebo on the primary and key secondary endpoints, driving investors to cut the cord holding up Athira's stock price. [ABSTRACT FROM AUTHOR]

Aelis Farma's hopes of securing a quick, positive decision on a $100 million option payment have gone up in smoke. [ABSTRACT FROM AUTHOR]

Recursion has stumbled through an early test of its tech-enabled drug discovery, reporting a hit on safety but failing to wow on the efficacy front. [ABSTRACT FROM AUTHOR]

Arrowhead Pharmaceuticals has shown its hand ahead of a potential showdown with Ionis, [ABSTRACT FROM AUTHOR]

The stem cell biotech is letting go of its listing after money troubles persuaded it to free itself from the costs and obligations of the exchange. [ABSTRACT FROM AUTHOR]

Allist is paying Jacobio Pharma $21 million for rights to a near-approval inhibitor of the KRAS oncogene and a potentially complementary molecule. [ABSTRACT FROM AUTHOR]

J&J has taken another step toward realizing a return on its $6.5 billion nipocalimab bet, filing for FDA approval to challenge argenx and UCB in gMG. [ABSTRACT FROM AUTHOR]

Neurocrine achieved its hoped-for profile in the schizophrenia trial but only saw efficacy at the lowest dose—the three higher doses all failed. [ABSTRACT FROM AUTHOR]

Duality Biotherapeutics is seeking an undisclosed amount of IPO proceeds to power a broad pipeline of antibody-drug conjugates toward approval. [ABSTRACT FROM AUTHOR]

The biotech identified "suboptimal exposure" to its tetra-specific T-cell engager as the cause of the limited response rate in its early-phase trial. [ABSTRACT FROM AUTHOR]

The biotech is seeking funding to take a would-be challenger to Ascendis Pharma's rare endocrine disease drug Yorvipath into phase 3 development. [ABSTRACT FROM AUTHOR]

Having built a 9.9% stake, EcoR1 Capital is planning to talk to the Belgian biotech about its performance and the composition of its board. [ABSTRACT FROM AUTHOR]

Lilly has expanded its partnership with Oblique, adding a second strand to an alliance focused on using the AbiProt platform to discover antibodies. [ABSTRACT FROM AUTHOR]

Bicara is seeking money to fund a phase 2/3 cancer trial and Zenas is running a pivotal autoimmune disease study. [ABSTRACT FROM AUTHOR]

BioAge named former Jean-Pierre Garnier as chair of its board, bringing the veteran into the anti-aging space years after he made a bet on the sector. [ABSTRACT FROM AUTHOR]

The FDA hit the Big Biotech's BCMAxCD3 bispecific antibody linvoseltamab with a complete response letter over issues at a third-party manufacturer. [ABSTRACT FROM AUTHOR]

Merck is continuing to tinker with its alliance with Kelun, agreeing to pay $37.5 million to option one ADC while returning rights to another. [ABSTRACT FROM AUTHOR]

BioMarin is shaking up its leadership team, raiding Amgen for an R&D chief and pulling off the coup of signing a high-profile former Roche dealmaker. [ABSTRACT FROM AUTHOR]

Metagenomi is seeking a partner for a program Moderna dropped and axing its amyotrophic lateral sclerosis activities in response to rivals' setbacks. [ABSTRACT FROM AUTHOR]

Rivus plumped up the prospects of its fat busting, muscle sparing drug candidate, reporting a primary endpoint hit in a phase 2a trial. [ABSTRACT FROM AUTHOR]

The facility boosts Lilly's RNA and DNA research capabilities and expands its biotech-hosting Gateway Labs to the East Coast for the first time. [ABSTRACT FROM AUTHOR]

Avidity impressed investors, but closer examinations revealed details that present a more nuanced picture than what the headline result implies. [ABSTRACT FROM AUTHOR]

Merck & Co. [ABSTRACT FROM AUTHOR]

The Big Pharma terminated a pivotal small cell lung cancer study after an interim review revealed efficacy and safety problems. [ABSTRACT FROM AUTHOR]

AN2 Therapeutics is rethinking its business in response to lackluster midphase data that have prompted a pivot to early-stage projects. [ABSTRACT FROM AUTHOR]